The CEO of Pfizer received loud boos when he was introduced by Donald Trump at a Black History Month event at the White House ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

The weakness was also weighing on shares of some of Walmart's rivals, as Costco Wholesale Corp.'s stock (COST) fell 2.2% and Target Corp. shares (TGT) shed 1.1%, to underperform the S&P 500 index's ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...

Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...

CardCash.com, Giftify's secondary gift card exchange platform, provides consumers with an innovative approach to reduce rising out-of-pocket expenses for increasingly popular GLP-1 medications. The ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Polar Capital Global Healthcare, which is co-managed by James Douglas, currently trades at a 3pc discount to its assets.